A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index; 28 of the 84 sources its claims cite were checked for support.
Abstract
Background: The differential diagnosis of frontotemporal dementia (FTD) is still a challenging task due to its symptomatic overlap with other neurological diseases and the lack of biofluid-based biomarkers. Objective: To investigate the diagnostic potential of a combination of novel biomarkers in cerebrospinal fluid (CSF) and blood. Methods: We included 135 patients from the Center for Memory Disturbances, University of Perugia, with the diagnoses FTD (n = 37), mild cognitive impairment due to Alzheimer’s disease (MCI-AD, n = 47), Lewy body dementia (PDD/DLB, n = 22), and cognitively unimpaired patients as controls (OND, n = 29). Biomarker levels of neuronal pentraxin-2 (NPTX2), neuronal pentraxin receptor, neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) were measured in CSF, as well as NfL and GFAP in serum. We assessed biomarker differences by analysis of covariance and generalized linear models (GLM). We performed receiver operating characteristics analyses and Spearman correlation to determine biomarker associations. Results: CSF NPTX2 and serum GFAP levels varied most between diagnostic groups. The combination of CSF NPTX2, serum NfL and serum GFAP differentiated FTD from the other groups with good accuracy (FTD versus MCI-AD: area under the curve (AUC) [95% CI] = 0.89 [0.81–0.96]; FTD versus PDD/DLB: AUC = 0.82 [0.71–0.93]; FTD versus OND: AUC = 0.80 [0.70–0.91]). CSF NPTX2 and serum GFAP correlated positively only in PDD/DLB (ρ= 0.56, p < 0.05). NPTX2 and serum NfL did not correlate in any of the diagnostic groups. Serum GFAP and serum NfL correlated positively in all groups (ρ= 0.47–0.74, p < 0.05). Conclusion: We show the combined potential of CSF NPTX2, serum NfL, and serum GFAP to differentiate FTD from other neurodegenerative disorders.
Overview
CoChat Summary
TL;DR
A retrospective single-center study found that a cross-matrix panel of CSF NPTX2, serum NfL, and serum GFAP discriminated frontotemporal dementia (FTD) from other dementia groups with AUCs around 0.80–0.89. The authors conclude the combination reflects synaptic, axonal, and astroglial pathology and may aid differential FTD diagnosis, though clinical use is limited by the need for both CSF and serum.
Key findings
- In 135 patients (FTD n=37, MCI-AD n=47, PDD/DLB n=22, OND n=29), CSF NPTX2 and serum GFAP varied most across diagnostic groups. CSF NPTX2 was lower in all diagnostic groups versus OND, and lowest in PDD/DLB; serum GFAP was higher in MCI-AD than OND, FTD, and PDD/DLB, and higher in FTD and PDD/DLB than OND.
- The combined model of CSF NPTX2, serum NfL, and serum GFAP differentiated FTD from other groups: FTD versus MCI-AD AUC 0.89 [0.81–0.96], sensitivity 84%, specificity 85%; FTD versus PDD/DLB AUC 0.82 [0.71–0.93], sensitivity 78%, specificity 86%; FTD versus OND AUC 0.80 [0.70–0.91], sensitivity 70%, specificity 83%.
- CSF NPTX2 and serum GFAP correlated positively only in PDD/DLB (ρ=0.56, p<0.05); serum GFAP and serum NfL correlated positively in all groups (ρ=0.47–0.74, p<0.05). CSF and serum NfL correlated strongly overall (ρ=0.77, p<0.001), while CSF and serum GFAP correlated moderately overall (ρ=0.50, p<0.001).
- CSF NPTX2 and CSF NPTXR correlated positively with MMSE (ρ=0.41 and ρ=0.33, both p<0.001), while serum NfL and serum GFAP correlated negatively with MMSE (ρ=–0.35 and ρ=–0.49, both p<0.001).
Methods
- Retrospective inclusion of 135 patients from the Center for Memory Disturbances, University of Perugia, between 2007 and 2018, with diagnoses of FTD, MCI-AD, PDD/DLB, or OND controls; final diagnoses used international criteria, neuropsychological testing, structural imaging, and FDG-PET for suspected FTD.
- CSF NPTX2, NPTXR, NfL, and GFAP and serum NfL and GFAP were measured by ELISA or Simoa assays; AD CSF biomarkers were used to define A/T/(N) profiles.
- Analyses included ANCOVA adjusted for age and sex with Tukey post-hoc tests, generalized linear models, ROC analyses, and Spearman correlations, with Bonferroni correction for multiple comparisons.
Limitations
- Stated: small diagnostic group sizes led to low statistical power; MCI-AD patients were included at the pre-dementia stage rather than dementia, though they converted within 12–18 months of lumbar puncture; the NPTXR ELISA did not meet optimal CSF measurement criteria, so NPTXR granularity may be suboptimal; the proposed combination requires both CSF and serum, while a blood-only panel would be preferred, and serum NPTX2 was not available.
- Evident from the text: this is a single-center retrospective study without independent replication; the FTD group includes small subtype subgroups; three FTD patients had co-occurring AD pathology (A+/T+), although the authors report main findings were retained after excluding them.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
18 Valid · 0 Not valid · 24 Not checked · 73 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Due to its clinical and pathological heterogeneity and symptomatic overlap with other neurodegenerative diseases, such as Alzheimer’s disease (AD), and other non-neurodegenerative psychiatric disorders, the differential diagnosis of FTD remains challenging [2, 7–9].”
- Also stated in: § Background: · plain
“The differential diagnosis of frontotemporal dementia (FTD) is still a challenging task due to its symptomatic overlap with other neurological diseases and the lack of biofluid-based biomarkers.”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > INTRODUCTION
What the sources say
- Supportedcites [2] Warren, 2013, Clinical review. Frontotemporal dementia, BMJ source
The Abstract (p.1) states FTD is 'a clinically and pathologically heterogeneous group of non-Alzheimer dementias,' supplying the heterogeneity element. The section 'How is frontotemporal dementia distinguished from other diseases?' states FTD must be distinguished from non-degenerative processes presenting with behavioural/executive/language disturbance (primary psychiatric illness, tumours, cerebrovascular disease) and from other neurodegenerative diseases, notably atypical Alzheimer's disease, and that the bvFTD–cerebrovascular distinction 'is more challenging'; a further passage ('What are the different syndromes of FTD?') says diagnosis 'is often challenging' and that behavioural/personality change may suggest a primary psychiatric disorder and language disturbance may be misattributed to psychological factors. Together these support the paraphrased claim of a difficult differential diagnosis driven by heterogeneity and symptomatic overlap. (LLM, conf=0.90)
- Not checked yetcites [7] Kertesz, 2005, The evolution and pathology of frontotemporal dementia, Brain source
- Not checked yetcites [8] Luscher, 2014, Frontotemporal Dementia (FTD) - even with revisited criteria a diagnostic challenge, Fortschr Neurol Psychiatr
- Partly supportedcites [9] Ducharme, 2020, Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders, Brain sourceExperimental — accuracy not yet measured
Our copy supports the core of the sentence for bvFTD: the Introduction (p. 4) states that 'the diagnosis of behavioural variant FTD (bvFTD) remains challenging because of the absence of such molecular biomarkers' and that 'the symptomatic overlap with non-degenerative primary psychiatric disorders (PPD)... means that PPD often constitute the main differential diagnosis of bvFTD' (echoed in the abstract, p. 2). However, the paper does not attribute the difficulty to FTD's clinical and pathological heterogeneity as such — heterogeneity appears only narrowly, e.g. C9orf72 cases presenting with 'heterogeneous neuropsychiatric phenotypes' 'adding to the complexity' (Introduction, p. 4) and phenocopy cases lacking FTLD pathology (Discussion, p. 14) — and it makes no claim of symptomatic overlap with other neurodegenerative diseases: Alzheimer's disease is mentioned only as a contrast whose diagnosis has become easier with amyloid PET/CSF biomarkers (Introduction, p. 4). The unsupported parts of the claim are the pathological-heterogeneity rationale and the overlap with AD/other neurodegenerative diseases; the source also concerns bvFTD specifically rather than FTD overall. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Background: · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“and in CSF, compared to AD patients [24, 26, 27].”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > INTRODUCTION
What the sources say
- Supportedcites [24] Landqvist Waldo, 2013, Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia, BMC Neurol source
The Abstract (Result) states 'NFL levels were significantly higher in FTD compared with both AD (p<0.001) and controls (p<0.001)', and the Results section ('CSF biomarkers in the clinical patient group') reports the median CSF NFL for the entire FTD group significantly higher than the AD group (p<0.001), with the Discussion adding that SD and bvFTD but not PNFA differed from AD. The cited comparison is thus made in CSF, in FTD versus AD, exactly as the citing sentence attributes it. The PNFA null result is a subgroup caveat not carried by the citing claim. (LLM, conf=0.93)
- Not checked yetcites [26] Bridel, 2019, Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis, JAMA Neurol source
- Not checked yetcites [27] Sjogren, 2000, Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD, Neurology source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“NPTXR in CSF was measured by ELISA from RayBiotech (RayBio® Human NPTXR ELISA Kit; RayBiotech, USA), which, albeit being used by other groups [93, 94], did not meet the optimal criteria for measurements in CSF when validated by our group.”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > DISCUSSION > Limitations
What the sources say
- Not checked yetcites [93] Lim, 2020, Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer’s disease: A 24-month follow-up study, Neurobiol Aging source
- Supportedcites [94] Dulewicz, 2021, Neurogranin and neuronal pentraxin receptor as synaptic dysfunction biomarkers in Alzheimer’s disease, J Clin Med source
The citation supports the parenthetical point that another group used the RayBiotech kit: Materials and Methods, §4.2, states that this paper measured CSF NPTXR with a RayBioHuman NPTXR ELISA kit. The statement that the kit failed validation criteria is expressly attributed to the citing authors’ own group, not to this source. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > DISCUSSION
What the sources say
- Not checked yetcites [33] Oeckl, 2019, Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment, J Alzheimers Dis source
- Supportedcites [75] Pereira, 2021, Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer’s disease, Brain source
The Results section 'Plasma GFAP is associated with early amyloid-β pathology' reports plasma GFAP significantly elevated in both amyloid-β-positive cognitively unimpaired and cognitively impaired groups versus amyloid-β-negative groups [F up to 24.14, P < 0.001], whereas the Abstract and Discussion state CSF GFAP 'was only associated with amyloid-β pathology in cognitively impaired individuals, showed less-steep increases with increasing amyloid-β-PET burden in the spline models' and had lower sensitivity/specificity than plasma GFAP (AUC 0.69 vs 0.76). Together these establish that, for GFAP, the differences between groups were more pronounced/consistent in blood (plasma) than in CSF, which is what the citing sentence attributes to this work. The only contrary-direction CSF finding (CSF GFAP elevated in non-Alzheimer's disease disorders) reinforces rather than undermines the plasma-over-CSF contrast for amyloid-β group separation. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As has been shown by Toledo et al., FTD biomarker studies can be confounded by AD co-pathology [91].”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > DISCUSSION
What the sources say
- Supportedcites [91] Toledo, 2012, CSF biomarkers cutoffs: The importance of coincident neuropathological diseases, Acta Neuropathol source
The Discussion says overlapping neuropathologies are often not correctly identified by current biomarkers and calls for more neuropathologically homogeneous FTD samples in biomarker studies. The neuropathological analysis explicitly identifies FTLD cases with concomitant AD pathology, supporting the stated potential for confounding. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
38 more claims
Create a free account to see all 115 claims and to verify the 56 references still open.
- Probably not a substantial claim. 55
- It may state two separate claims as one. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, some studies reported elevated blood GFAP in participants with FTD compared to controls [8–18] but others observed no such GFAP increase in FTD [19–22].”
From Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders (2025) · cites this paper as [16]
In the citing paper
“Synaptic protein Ng was measured using a commercial ELISA from EuroImmun, while the other synaptic proteins SNAP25, NPTX2, and GluR4 were measured using novel immunoassays developed and validated as per standardized protocols at ADx NeuroSciences, described in detail elsewhere [15,36,37].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > RESULTS > Correlations of study biomarkers with MMSE scores
“C-F) MMSE scores correlated negatively with NfL and GFAP in serum but did not reach significance in CSF.”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > RESULTS > Correlations of study biomarkers with MMSE scores
“This correlation was less pronounced in CSF (Fig. 2C: NfL: ρ= –0.21, p = 0.018; Fig. 1E: GFAP: ρ= –0.19, p = 0.032).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > RESULTS > Correlations of serum and CSF biomarkers
“D) GFAP in serum and CSF correlated in PDD/DLB, and showed a positive trend in OND and MCI-AD. No correlation was observed in FTD.”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > RESULTS > Correlations of serum and CSF biomarkers
“Serum and CSF GFAP correlated moderately in OND (ρ= 0.58, p < 0.01) and PDD/DLB (ρ= 0.57, p < 0.05), but not in FTD (not significant (n.s.)).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| A+ | 73 | 2 | 11 | 45 | 15 | | | (58.40%) | (6.90%) | (29.73%)1 | (95.74%)1,2 | (68.18%)1,2,3 |”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > RESULTS > Demographics
Reported 58.4 · recomputed 54.074074
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > RESULTS > Correlations of combined biomarkers
“B) When stratified for diagnoses, serum and CSF NfL did not correlate in any of the diagnostic groups.”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > RESULTS > Correlations of serum and CSF biomarkers
“Correlations between CSF and serum NfL, stratified for diagnostic groups, were significant in all diagnostic groups (ρ= 0.66 –0.83, p < 0.001) (Fig. 5C).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > DISCUSSION
“This exploratory study investigated whether NfL, GFAP, NPTX2, and NPTXR in CSF and/or serum could have an added value for the differential diagnosis of FTD in a cohort of 137 patients diagnosed with FTD, MCI-AD, PDD/DLB, and OND.”
§ A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias > Abstract > Methods:
“We included 135 patients from the Center for Memory Disturbances, University of Perugia, with the diagnoses FTD (n = 37), mild cognitive impairment due to Alzheimer’s disease (MCI-AD, n = 47), Lewy body dementia (PDD/DLB, n = 22), and cognitively unimpaired patients as controls (OND, n = 29).”
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“Cerebrospinal fluid (CSF) biomarkers are already implemented to support the diagnosis of AD [11, 12], and there has been great progress concerning their measurement in blood [13].”
Simultaneous Inference in General Parametric Models
Hothorn, T., Bretz, F., & Westfall, P. (2008) · Biometrical Journal · doi:10.1002/bimj.200810425 · Cited by 13,847 · cited 1×
“The comparisons of biomarker levels between the diagnostic groups were evaluated with one-way analysis of covariance (ANCOVA, car R package [57]), adjusted for the effect of age and sex, with subsequent Tukey’s post-hoc test for pairwise comparisons (multcomp R package [58]).”
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697 · cited 1×
“Finally, receiver operating characteristics (ROC) curves were constructed (pROC R package [59]), again containing the respective diagnosis as outcome and age, sex, and respective biomarkers as predictors.”
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“, Mini Mental State Examination (MMSE) [47], further tests for each cognitive domain, and the Clinical Dementia Rating Scale (CDR) were carried out [48].”
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · cited 1×
“Furthermore, a breakdown of the blood brain barrier has been shown in neurodegenerative diseases [81, 82].”
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
The Mini-Mental State Examination
Folstein, M. F. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790060110016 · Cited by 1,936 · cited 9×
“Associations of study biomarkers with MMSE, age, sex, and in-between study biomarkers were analyzed using Spearman’s rank-order correlation and p-values were adjusted for multiple comparisons by Bonferroni correction.”
InfluentialBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159 · cited 1×
“Cerebrospinal fluid (CSF) biomarkers are already implemented to support the diagnosis of AD [11, 12], and there has been great progress concerning their measurement in blood [13].”
The prevalence of frontotemporal dementia
Ratnavalli, E., Brayne, C., Dawson, K., & Hodges, J. R. (2002) · Neurology · doi:10.1212/wnl.58.11.1615 · Cited by 1,157
Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker
Yang, Z., & Wang, K. K. W. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.04.003 · Cited by 1,050 · cited 1×
“The highly brain-specific protein GFAP has been studied as a potential marker for astrocytic activation and gliosis, upon which its production is being upregulated [29, 30].”
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · cited 1×
“Sample collection was performed according to international guidelines [53].”
Self-citationBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764 · cited 1×
“In FTD patients it has been shown to be increased in CSF and serum, compared to cognitively healthy controls [23–26], and in CSF, compared to AD patients [24, 26, 27].”
Self-citationSofroniew, M. V. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020420 · Cited by 695
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review
Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A. L., Fox, N. C., & van Swieten, J. C. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.212225 · Cited by 609
The evolution and pathology of frontotemporal dementia
Kertesz, A., McMonagle, P., Blair, M., Davidson, W., & Munoz, D. G. (2005) · Brain · doi:10.1093/brain/awh598 · Cited by 609
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598 · cited 1×
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
Self-citationKramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571 · cited 2×
“This difference might result from PDD and DLB being Lewy body diseases characterized by synuclein accumulations, as indicated above [71, 72], while AD and FTD are caused by the accumulation of different proteins leading to distinct pathological mechanisms.”
A practical guide to immunoassay method validation
Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00179 · Cited by 546 · cited 1×
“CSF NPTX2 concentrations were measured using a newly developed ELISA from ADx Neurosciences (ADx Neurosciences NV, Belgium) that was validated according to international consensus criteria [54] at the Neurochemistry Laboratory of the Amsterdam University Medical Center in the Netherlands (validation results are report…”
Self-citationNeary, D., Snowden, J., & Mann, D. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70223-4 · Cited by 526
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., Bestwick, J. P., Monsch, A. U., Regeniter, A., Lindberg, R. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075091 · Cited by 486 · cited 1×
“for overall neurodegeneration [60, 61]), and GFAP (depicting astrogliosis [62]) reflects the complexity of pathological mechanisms involved in neurodegenerative disorders and FTD in particular [63–66] Interestingly, these combined biomarkers showed different correlations with each other, depending on the different dia…”
Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439
Self-citationOeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Huss, A. M., Neugebauer, H., von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180325 · Cited by 345 · cited 3×
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
Ducharme, S., Dols, A., Laforce, R., Devenney, E., Kumfor, F., van den Stock, J., Dallaire-Théroux, C., Seelaar, H., Gossink, F., Vijverberg, E., et al. (2020) · Brain · doi:10.1093/brain/awaa018 · Cited by 320 · cited 1×
“Blood NfL has already been implemented in the novel guidelines for differentiating FTD from non-degenerative primary psychiatric disorders [9, 25].”
Primary Progressive Aphasia: Longitudinal Course, Neuropsychological Profile, and Language Features
Weintraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 310
A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia
Huey, E. D., Putnam, K. T., & Grafman, J. (2006) · Neurology · doi:10.1212/01.wnl.0000191304.55196.4d · Cited by 299 · cited 1×
“To date, no FTD-specific diagnostic tests or disease-modifying treatments are available and misdiagnosis often leads to an unsuitable care approach or wrong medication that can worsen the symptoms [10].”
Warren, J. D., Rohrer, J. D., & Rossor, M. N. (2013) · BMJ · doi:10.1136/bmj.f4827 · Cited by 292
Neuroinflammation in frontotemporal dementia
Bright, F., Werry, E. L., Dobson-Stone, C., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kassiou, M., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0231-z · Cited by 280
Astroglial cradle in the life of the synapse
Verkhratsky, A., & Nedergaard, M. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0595 · Cited by 266 · cited 1×
“Astroglia are interacting with synapses and forming part of the synapse structure [86, 87], which could be an explanation for the positive association between serum GFAP and CSF NPTX2.”
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263 · cited 1×
“Increased levels of NfL in CSF and serum, indicating axonal loss, correlated with increased cognitive impairment, as has been shown previously [73, 74], with a stronger correlation in serum than in CSF.”
Verberk, I. M. W., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., de Wilde, A., Zwan, M. D., Verfaillie, S. C. J., Ossenkoppele, R., Barkhof, F., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00682-7 · Cited by 258
Self-citationPelkey, K. A., Barksdale, E., Craig, M. T., Yuan, X., Sukumaran, M., Vargish, G. A., Mitchell, R. M., Wyeth, M. S., Petralia, R. S., Chittajallu, R., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.020 · Cited by 245
Brenner, M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.055 · Cited by 222 · cited 2×
“a deterioration of the underlying disease pathology by the accumulation of cytotoxic factors [29, 85].”
Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia
Skillbäck, T., Farahmand, B. Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., Schott, J. M., et al. (2015) · Brain · doi:10.1093/brain/awv181 · Cited by 217 · cited 1×
“At present, the classical AD CSF biomarkers, namely amyloid1–42 (A 42), tau phosphorylated at threonine 181 (p-tau), total tau (t-tau), and related ratios, are being used to exclude AD as a differential diagnosis of FTD [14].”
Frontotemporal dementia: latest evidence and clinical implications
Young, J. J., Lavakumar, M., Tampi, D., Balachandran, S., & Tampi, R. R. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317739818 · Cited by 186
Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
Heller, C., Foiani, M. S., Moore, K., Convery, R., Bocchetta, M., Neason, M., Cash, D. M., Thomas, D., Greaves, C. V., Woollacott, I. O., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321954 · Cited by 182
CSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · cited 1×
“, FTD biomarker studies can be confounded by AD co-pathology [91].”
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Sjögren, M., Rosengren, L., Minthon, L., Davidsson, P., Blennow, K., & Wallin, A. (2000) · Neurology · doi:10.1212/wnl.54.10.1960 · Cited by 181 · cited 1×
“In FTD patients it has been shown to be increased in CSF and serum, compared to cognitively healthy controls [23–26], and in CSF, compared to AD patients [24, 26, 27].”
Forgrave, L. M., Ma, M., Best, J. R., & DeMarco, M. L. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.009 · Cited by 177 · cited 1×
“for overall neurodegeneration [60, 61]), and GFAP (depicting astrogliosis [62]) reflects the complexity of pathological mechanisms involved in neurodegenerative disorders and FTD in particular [63–66] Interestingly, these combined biomarkers showed different correlations with each other, depending on the different dia…”
Astrogliosis as a therapeutic target for neurodegenerative diseases
Colangelo, A. M., Alberghina, L., & Papa, M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.014 · Cited by 176 · cited 1×
“for overall neurodegeneration [60, 61]), and GFAP (depicting astrogliosis [62]) reflects the complexity of pathological mechanisms involved in neurodegenerative disorders and FTD in particular [63–66] Interestingly, these combined biomarkers showed different correlations with each other, depending on the different dia…”
Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia
Lall, D., & Baloh, R. H. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90607 · Cited by 175
Pentraxins as a key component of innate immunity
Bottazzi, B., Garlanda, C., Salvatori, G., Jeannin, P., Manfredi, A., & Mantovani, A. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.009 · Cited by 168 · cited 1×
“Neuronal pentraxins have been found to be involved in synapse formation and plasticity [37, 38], and have been proposed to have a protective function against neurodegeneration [34, 39, 40].”
Ishiki, A., Kamada, M., Kawamura, Y., Terao, C., Shimoda, F., Tomita, N., Arai, H., & Furukawa, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13399 · Cited by 156 · cited 1×
“Already at early stages of FTD, apoptosis and dystrophy of astrocytes have been found in the brain [31] and high levels of GFAP have been detected in CSF and blood [32, 33].”
Serum NFL discriminates Parkinson disease from atypical parkinsonisms
Marques, T. M., van Rumund, A., Oeckl, P., Kuiperij, H. B., Esselink, R. A. J., Bloem, B. R., Otto, M., & Verbeek, M. M. (2019) · Neurology · doi:10.1212/wnl.0000000000007179 · Cited by 153 · cited 1×
“We observed strong correlations between CSF and serum levels for NfL, as it has been previously reported [31, 88, 89].”
Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses
Lee, S.-J., Wei, M., Zhang, C., Maxeiner, S., Pak, C., Calado Botelho, S., Trotter, J., Sterky, F. H., & Südhof, T. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2768-16.2016 · Cited by 146 · cited 1×
“Neuronal pentraxins have been found to be involved in synapse formation and plasticity [37, 38], and have been proposed to have a protective function against neurodegeneration [34, 39, 40].”
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133
Self-citationThe Role of Neuroinflammation in Dementias
Pasqualetti, G., Brooks, D. J., & Edison, P. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0531-7 · Cited by 133 · cited 2×
“a deterioration of the underlying disease pathology by the accumulation of cytotoxic factors [29, 85].”
Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., & Englund, E. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-54 · Cited by 127 · cited 1×
“In FTD patients it has been shown to be increased in CSF and serum, compared to cognitively healthy controls [23–26], and in CSF, compared to AD patients [24, 26, 27].”
Sathe, G., Na, C. H., Renuse, S., Madugundu, A. K., Albert, M., Moghekar, A., & Pandey, A. (2019) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201800105 · Cited by 126 · cited 1×
“Several proteomics studies have identified neuronal pentraxins to be deregulated in the CSF of patients with neurodegenerative diseases [22, 41, 42].”
Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum
Meeter, L. H. H., Vijverberg, E. G., Del Campo, M., Rozemuller, A. J. M., Donker Kaat, L., de Jong, F. J., van der Flier, W. M., Teunissen, C. E., van Swieten, J. C., & Pijnenburg, Y. A. L. (2018) · Neurology · doi:10.1212/wnl.0000000000005261 · Cited by 122
Self-citationFluid biomarkers in frontotemporal dementia: past, present and future
Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122 · cited 1×
“In FTD, neuronal pentraxin-2 (NPTX2) and neuronal pentraxin receptor (NPTXR) have been found to be decreased in symptomatic genetic mutation carriers compared to non-carriers and pre-symptomatic carriers [43, 44].”
Serum neurofilament light chain in behavioral variant frontotemporal dementia
Steinacker, P., Anderl-Straub, S., Diehl-Schmid, J., Semler, E., Uttner, I., von Arnim, C. A. F., Barthel, H., Danek, A., Fassbender, K., Fliessbach, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006318 · Cited by 116 · cited 1×
“Increased levels of NfL in CSF and serum, indicating axonal loss, correlated with increased cognitive impairment, as has been shown previously [73, 74], with a stronger correlation in serum than in CSF.”
Benussi, A., Ashton, N. J., Karikari, T. K., Gazzina, S., Premi, E., Benussi, L., Ghidoni, R., Rodriguez, J. L., Emeršič, A., Binetti, G., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200608 · Cited by 113
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112
Astrocytic degeneration relates to the severity of disease in frontotemporal dementia
Broe, M. (2004) · Brain · doi:10.1093/brain/awh250 · Cited by 106 · cited 2×
“Already at early stages of FTD, apoptosis and dystrophy of astrocytes have been found in the brain [31] and high levels of GFAP have been detected in CSF and blood [32, 33].”
Teunissen, C. E., Elias, N., Koel‐Simmelink, M. J. A., Durieux‐Lu, S., Malekzadeh, A., Pham, T. V., Piersma, S. R., Beccari, T., Meeter, L. H. H., Dopper, E. G. P., et al. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.12.004 · Cited by 103 · cited 1×
“Multiple proteomics studies identified potential FTD-specific biomarker candidates [15, 16], of which some have been further studied in CSF and blood [17–19].”
Self-citationNeuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322493 · Cited by 94
Self-citationOeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., Baldeiras, I., Diehl-Schmid, J., Grimmer, T., Halbgebauer, S., Kort, A. M., Lima, M., Marques, T. M., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328547 · Cited by 94
Astrocytes in the regulation of cerebrovascular functions
Cohen‐Salmon, M., Slaoui, L., Mazaré, N., Gilbert, A., Oudart, M., Alvear‐Perez, R., Elorza‐Vidal, X., Chever, O., & Boulay, A. (2021) · Glia · doi:10.1002/glia.23924 · Cited by 93 · cited 2×
“This correlation reflects the interaction of neurodegeneration and astrogliosis in the CNS: glial cells are activated in response to degeneration, but also infection or injury, exerting neuroprotective and neurotoxic effects to maintain homeostasis [85].”
Zhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00275-w · Cited by 86 · cited 1×
“The combination of blood GFAP and NfL has already shown promising diagnostic potential for the differentiation of FTD, AD, and controls [92], and a combined 2-plex assay has been developed and brought to market by Quanterix (NEUROLOGY 2PLEX B (Nf-L, GFAP*) Quanterix, USA).”
van Steenoven, I., Koel-Simmelink, M. J. A., Vergouw, L. J. M., Tijms, B. M., Piersma, S. R., Pham, T. V., Bridel, C., Ferri, G.-L., Cocco, C., Noli, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00388-2 · Cited by 83 · cited 2×
“The decrease of neuronal pentraxins in the Lewy body dementias groups corroborates our previous findings [41] and could be due to the accumulation of these proteins in Lewy bodies, as it has been found for NPTX2 in Parkinson’s disease [67].”
Self-citationThe pericyte–glia interface at the blood–brain barrier
Giannoni, P., Badaut, J., Dargazanli, C., De Maudave, A. F., Klement, W., Costalat, V., & Marchi, N. (2018) · Clinical Science · doi:10.1042/cs20171634 · Cited by 81 · cited 1×
“Furthermore, a breakdown of the blood brain barrier has been shown in neurodegenerative diseases [81, 82].”
Swanson, A., & Willette, A. A. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.148 · Cited by 79
Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum
Wilke, C., Preische, O., Deuschle, C., Roeben, B., Apel, A., Barro, C., Maia, L., Maetzler, W., Kuhle, J., & Synofzik, M. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312972 · Cited by 79 · cited 1×
“Blood NfL has already been implemented in the novel guidelines for differentiating FTD from non-degenerative primary psychiatric disorders [9, 25].”
Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD
Starr, A., & Sattler, R. (2018) · Brain Research · doi:10.1016/j.brainres.2018.02.011 · Cited by 78
Neuroinflammation in Alzheimer’s disease: Pleiotropic roles for cytokines and neuronal pentraxins
Swanson, A., Wolf, T., Sitzmann, A., & Willette, A. A. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.02.015 · Cited by 72
A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes
Lleó, A., Irwin, D. J., Illán-Gala, I., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0118 · Cited by 71 · cited 1×
“Three of the included FTD patients presented with co-occurring AD pathology (A+/T+), which is a frequent clinical FTD manifestation [90].”
Moran, L. B., Hickey, L., Michael, G. J., Derkacs, M., Christian, L. M., Kalaitzakis, M. E., Pearce, R. K. B., & Graeber, M. B. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0309-3 · Cited by 69 · cited 1×
“The decrease of neuronal pentraxins in the Lewy body dementias groups corroborates our previous findings [41] and could be due to the accumulation of these proteins in Lewy bodies, as it has been found for NPTX2 in Parkinson’s disease [67].”
Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez‐Valle, R., Graff, C., Öijerstedt, L., Grossman, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.745 · Cited by 65 · cited 2×
“[16, 21], and neuronal pentraxins [22].”
The role of neurofilament light chain in frontotemporal dementia: a meta-analysis
Karantali, E., Kazis, D. A., Chatzikonstantinou, S., Petridis, F., & Mavroudis, I. A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01554-8 · Cited by 57 · cited 1×
“Some of the promising biomarker candidates identified for FTD are neurofilament light (NfL) [20, 21], glial fibrillary acidic protein (GFAP)”
The Role of Neuronal Pentraxin 2 (NP2) in Regulating Glutamatergic Signaling and Neuropathology
Chapman, G., Shanmugalingam, U., & Smith, P. D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00575 · Cited by 56 · cited 1×
“(representing synaptic plasticity [35]), NfL (marker”
Perkins, E. M., Burr, K., Banerjee, P., Mehta, A. R., Dando, O., Selvaraj, B. T., Suminaite, D., Nanda, J., Henstridge, C. M., Gillingwater, T. H., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00433-8 · Cited by 54
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52 · cited 1×
“Some of the promising biomarker candidates identified for FTD are neurofilament light (NfL) [20, 21], glial fibrillary acidic protein (GFAP)”
Self-citationMoreno-Rodriguez, M., Perez, S. E., Nadeem, M., Malek-Ahmadi, M., & Mufson, E. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1723-x · Cited by 51 · cited 1×
“Also in cortical brain tissue, a similar trend for decreased NPTX2 levels in AD was observed [68].”
Review: Fluid biomarkers for frontotemporal dementias
Zetterberg, H., van Swieten, J. C., Boxer, A. L., & Rohrer, J. D. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12530 · Cited by 48
Boiten, W., van Steenoven, I., Xiao, M.-F., Worley, P., Noli, B., Cocco, C., Ferri, G.-L., Lemstra, A., & Teunissen, C. (2020) · Cells · doi:10.3390/cells10010038 · Cited by 42 · cited 2×
“This difference might result from PDD and DLB being Lewy body diseases characterized by synuclein accumulations, as indicated above [71, 72], while AD and FTD are caused by the accumulation of different proteins leading to distinct pathological mechanisms.”
Self-citationLim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.013 · Cited by 39 · cited 1×
“Human NPTXR ELISA Kit; RayBiotech, USA), which, albeit being used by other groups [93, 94], did not meet the optimal criteria for measurements in CSF when validated by our group.”
Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.12.010 · Cited by 33 · cited 1×
“Multiple proteomics studies identified potential FTD-specific biomarker candidates [15, 16], of which some have been further studied in CSF and blood [17–19].”
Blood biomarkers in frontotemporal dementia: Review and meta-analysis
Ntymenou, S., Tsantzali, I., Kalamatianos, T., Voumvourakis, K. I., Kapaki, E., Tsivgoulis, G., Stranjalis, G., & Paraskevas, G. P. (2021) · Brain Sciences · doi:10.3390/brainsci11020244 · Cited by 31 · cited 1×
“This observation strengthens the notion that serum NfL and GFAP can be used as accurate, but less invasive biomarkers than CSF NfL and GFAP [19].”
Körtvelyessy, P., Heinze, H. J., Prudlo, J., & Bittner, D. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00504 · Cited by 31
Novel CSF biomarkers to discriminate FTLD and its pathological subtypes
del Campo, M., Galimberti, D., Elias, N., Boonkamp, L., Pijnenburg, Y. A., van Swieten, J. C., Watts, K., Paciotti, S., Beccari, T., Hu, W., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.629 · Cited by 30
Self-citationAssociation between serum NPTX2 and cognitive function in patients with vascular dementia
Shao, K., Shan, S., Ru, W., & Ma, C. (2020) · Brain and Behavior · doi:10.1002/brb3.1779 · Cited by 25 · cited 1×
“(2020) suggests detection of NPTX2 in serum showing differential levels between vascular dementia patients and controls [95], however, the brain-specificity of NPTX2 in serum should be explored by correlating NPTX2 levels between serum and CSF.”
Pelkey, K. A., Barksdale, E., Craig, M. T., Yuan, X., Sukumaran, M., Vargish, G. A., Mitchell, R. M., Wyeth, M. S., Petralia, R. S., Chittajallu, R., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.024 · Cited by 22 · cited 1×
“Neuronal pentraxins have been found to be involved in synapse formation and plasticity [37, 38], and have been proposed to have a protective function against neurodegeneration [34, 39, 40].”
Dulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194575 · Cited by 22 · cited 1×
“Human NPTXR ELISA Kit; RayBiotech, USA), which, albeit being used by other groups [93, 94], did not meet the optimal criteria for measurements in CSF when validated by our group.”
Pentraxins in Innate Immunity and Inflammation
Garlanda, C., Bottazzi, B., Salvatori, G., Santis, R. D., Cotena, A., Deban, L., Maina, V., Moalli, F., Doni, A., Veliz‐Rodriguez, T., et al. (2006) · Novartis Foundation symposium · doi:10.1002/9780470035399.ch7 · Cited by 17
Heller, C., Chan, E., Foiani, M. S., Todd, E., Russell, L. L., Greaves, C. V., Heslegrave, A. J., Warren, J. D., Zetterberg, H., Bocchetta, M., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325085 · Cited by 15
Lim, B., Fowler, C., Li, Q.-X., Rowe, C., Dhiman, K., Gupta, V. B., Masters, C. L., Doecke, J. D., Martins, R. N., Collins, S., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135078 · Cited by 10 · cited 1×
“Both NPTX2 and NPTXR correlated positively with MMSE scores, as has been previously shown by other groups [69, 70], indicating a possible association with cognitive decline.”
Lüscher, S., Schwerthöffer, D., & Diehl‐Schmid, J. (2014) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0034-1365978 · Cited by 1
Research works printed but not linked: 2
- Luscher, 2014, Frontotemporal Dementia (FTD) - even with revisited criteria a diagnostic challenge, Fortschr Neurol Psychiatr, 82, 267
- Benedet Al, 2021, Differencesbetween plasma and cerebrospinal fluid glial fibrillary acidicprotein levels across the Alzheimer Disease Continuum, JAMANeurol, 78, 1471
Cited by
Nilsson, J., Binette, A. P., Palmqvist, S., Brum, W. S., Janelidze, S., Ashton, N. J., Spotorno, N., Stomrud, E., Gobom, J., Zetterberg, H., et al. (2024) · Brain · doi:10.1093/brain/awae032 · Cited by 92
Blood Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-Analysis
Holper, S., Loveland, P. M., Churilov, L. P., Italiano, D., Watson, R., & Yassi, N. (2024) · Neurology · doi:10.1212/wnl.0000000000209537 · Cited by 45
Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review
Liampas, I., Kyriakoulopoulou, P., Karakoida, V., Kavvoura, P. A., Sgantzos, M. N., Bogdanos, D. P., Stamati, P., Dardiotis, E., & Siokas, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111838 · Cited by 25
“Several studies have reported that the combination of CSF and/or blood biomarkers elevates the diagnostic accuracy in the evaluation of cognitively impaired individuals [69,126,127,150–154].”
BackgroundInfluentialZou, Y., Wang, Y., Ma, X., Mu, D., Zhong, J., Ma, C., Mao, C., Yu, S., Gao, J., & Qiu, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102485 · Cited by 26
Investigation of Inflammation in Lewy Body Dementia: A Systematic Scoping Review
Loveland, P. M., Yu, J. J., Churilov, L. P., Yassi, N., & Watson, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512116 · Cited by 24
Metadata
- Authors
- Bolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., & Willemse, E. A. J.
- Affiliations
- Amsterdam Neuroscience (NL)
- Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands
- University of Perugia (IT)
- ADx NeuroSciences (BE)
- Corresponding author
- Bolsewig, Katharina
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2022-10-25
- Volume
- 90
- Issue
- 1
- Pages
- 363-380
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC9661338
- OpenAlex
- W4296077746
- Cited by
- 36
- References
- 95
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 19 · 2023: 4
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- European Commission (HORIZON2020, 860197)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- frontotemporal dementia, differential diagnosis of dementia
- MeSH terms
- Pentraxins, Alzheimer Disease, Glial Fibrillary Acidic Protein, Humans, Intermediate Filaments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurofilament Proteins, Lewy Body Disease, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.